Synta Pharmaceuticals Corp. is focused on research, development and commercialization of oncology medicines. The Company's segment is the discovery, development and commercialization of drug products. It has a clinical-stage drug candidate in oncology (ganetespib), and a small molecule cancer drug development program (heat shock protein 90 (Hsp90) inhibitor Drug Conjugate (HDC) program). It is engaged in evaluating various candidates from its HDC program, which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver a range of anti-cancer payloads. Ganetespib is a small molecule inhibitor of Hsp90, a molecular chaperone that is required for the folding and activation of various cancer-promoting proteins. It is engaged in conducting preclinical studies for its clinical candidate from the HDC program, STA-12-8666. It holds interests in its drug candidate, elesclomol, and the calcium release-activated calcium modulator (CRACM) inhibitor program.